Semaglutide Cuts Cardiovascular Events in Landmark Trial
Mitchel L. Zoler, PhD August 08, 2023 The popular but expensive weight-loss drug, semaglutide (Wegovy), significantly reduced major adverse cardiovascular events (MACE) by 20% when given to patients, compared with those receiving placebo, in the pivotal SELECT trial, with more than 17,000 enrolled people with overweight or obesity and established cardiovascular disease (CVD), but no diabetes. The…
